The verdict
Our read at a glance.
Whether ketamine and esketamine's approved and trial-supported use in severe depression supports the broader mood, wellness, and at-home claims attached to them.
- The signal
- Esketamine is FDA-approved for treatment-resistant depression and for depression with suicidal thoughts, based on randomized trials, and racemic ketamine has substantial trial evidence for rapid, short-lived antidepressant effects. Benefits can fade without continued treatment, and the drugs require supervision.
- The unknown
- How to maintain benefit safely over time, the risks of long-term and less-supervised use, and how to separate evidence-based use from loosely regulated clinic and at-home models.
- Our read
- A genuine, fast-acting advance for severe depression, used under supervision, not a casual wellness treatment. Esketamine is approved and ketamine is well studied for depression, but the dissociation, abuse, and monitoring requirements mean the safe use is the supervised, specific-indication one.
The mechanism
How it works.
Ketamine is a dissociative anesthetic, and esketamine is its more potent S-enantiomer. Both block the NMDA glutamate receptor, and the leading explanation is that this blockade produces a rebound surge of glutamate that drives AMPA-receptor signaling and, downstream, the rapid formation of new synaptic connections. That synaptic effect is thought to explain why a single dose can lift severe depression within hours, unlike serotonin-based antidepressants that take weeks. The dissociation and sedation come from the same NMDA blockade, and dosing is supervised.
Safety & regulatory boundary
The consequential part.
Esketamine is approved only with a risk program requiring in-clinic administration and monitoring because of dissociation, sedation, blood-pressure effects, and abuse potential. Racemic ketamine for depression is largely off-label and also carries abuse and bladder and cognitive risks with heavy use. Approved supervised use does not validate unsupervised at-home or wellness use, and these are controlled drugs, not supplements.
What's next
What we're watching.
Long-term outcome and safety data, the role of at-home and off-label models, and regulatory actions on ketamine clinics.
Context
Why this is discussed.
Ketamine and esketamine are a major shift in depression treatment because they work quickly and differently from standard antidepressants, which has driven both clinical use and a wave of clinics and at-home offerings.
The evidence base
21 cited references.
Regulatory & labels1
Janssen Pharmaceuticals Inc. (FDA label) · 2026
Registered trials8
ClinicalTrials.gov · PHASE4 · RECRUITING · 2024-06-03
ClinicalTrials.gov · PHASE4 · NOT_YET_RECRUITING · 2026-07-01
ClinicalTrials.gov · NA · NOT_YET_RECRUITING · 2026-06-01
ClinicalTrials.gov · PHASE1 · NOT_YET_RECRUITING · 2026-05-01
ClinicalTrials.gov · NOT_YET_RECRUITING · 2026-05-30
ClinicalTrials.gov · NA · NOT_YET_RECRUITING · 2026-05-15
ClinicalTrials.gov · PHASE4 · COMPLETED · 2025-05-06
ClinicalTrials.gov · NA · NOT_YET_RECRUITING · 2026-04-27
Indexed literature (PubMed)12
McIntyre RS et al. · Am J Psychiatry · 2021
Feeney A et al. · Psychiatr Clin North Am · 2023
Reif A et al. · N Engl J Med · 2023
Nikayin S et al. · Expert Opin Drug Saf · 2022
Bahji A et al. · J Affect Disord · 2021
Medeiros GC et al. · Transl Psychiatry · 2024
Kim JW et al. · Annu Rev Med · 2024
Daly EJ et al. · JAMA Psychiatry · 2019
Fountoulakis KN et al. · Am J Psychiatry · 2025
Bahji A et al. · Expert Opin Drug Saf · 2022
Popova V et al. · Am J Psychiatry · 2019
Janik A et al. · JAMA Psychiatry · 2025
Keep reading